Patrick Moore

Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial

Alasdair Munro, Shuo Feng, Leila Janani et al. · The Lancet Infectious Diseases · 2022 · 170 citations · Full text

Safety and Efficacy of the NVX-CoV2373 Coronavirus Disease 2019 Vaccine at Completion of the Placebo-Controlled Phase of a Randomized Controlled Trial

Paul T. Heath, Eva Galiza, D. N. Baxter et al. · Clinical Infectious Diseases · 2022 · 72 citations · Full text

Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial.

Xinxue Liu, Alasdair Munro, Shuo Feng et al. · Journal of Infection · 2022 · 64 citations · Full text

Omicron BA.1-containing mRNA-1273 boosters compared with the original COVID-19 vaccine in the UK: a randomised, observer-blind, active-controlled trial

Ivan T. Lee, Catherine A. Cosgrove, Patrick Moore et al. · The Lancet Infectious Diseases · 2023 · 52 citations · Full text

Vaccinology, Vaccine Safety, Vaccination +10

Experience with Intraaortic Balloon Counterpulsation

Peter M. Sanfelippo, N. H. Baker, H. Gene Ewy et al. · The Annals of Thoracic Surgery · 1986 · 45 citations

Surgery, Intraaortic Balloon Counterpulsation, Stabilization (Medicine)